Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07809802) titled 'Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment' on Sept. 3.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).

Primary Sponsor: Betta Pharmaceuticals Co., Ltd.

Condition: Hepatic Impairment (HI)

Intervention: Drug: vorolanib Drug: vorolanib

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: September 2026

Target Sample Size: 36

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07809802

Publi...